The pharmacist’s knowledge of USP 800 guidance is critical for safe drug handling in all pharmacy practice settings. The USP 800 guidance will become effective December 2019. The information provided in this CE will assist pharmacists in protecting patients, themselves, and other healthcare providers from hazardous drugs. This course will provide an overview of USP 800 and the NIOSH list of hazardous drugs. Further, participants can expect to review proper handling of hazardous drugs according to USP 800 and to discuss how to develop a plan to safe handling of hazardous drugs at their practice site.

This module (1.0 CE), along with the other three MCPHS sterile compounding CE modules, ‘Parenteral Nutrition CSPs-2020 Update' (2.0 CE), ‘History and Basics - Aseptic Technique USP 797, 2019/20’ (1.5 CE), and ‘503b Outsourcing Facilities' (0.5 CE), total to 5.0 credits of sterile compounding. 

Learning Objectives
Upon completion of this activity, the participant should be able to:

• Outline the USP 800 regulation and importance across all practice sites.
  
• Identify potentially hazardous drugs using the NIOSH list.
  
• Demonstrate proper handling of hazardous drugs.
  
• Develop a plan for safe handling of hazardous drugs at your site.
• Educate other healthcare professionals on the safe handling of hazardous drugs.
  

Kaitlin Bova, PharmD
Katie earned her PharmD at Ohio Northern University and has had diverse internship experiences during her pharmacy training including working in an independent compounding pharmacy, an investigational drug service, a large academic medical center, and the United States Pharmacopeia. Katie joined the NIBR Quality team in July 2018 for the two year Massachusetts College of Pharmacy and Health Sciences Pharmaceutical Industry Fellowship Program. The fellowship program is designed to provide PharmD graduates with specialized training within the biopharmaceutical industry. At NIBR Quality, Katie has been working closely with the Translational Medicines clinical quality team to manage quality issues and events and perform inspection readiness activities for early phase clinical trials. Katie also works on various quality improvement projects and has been active in promoting the quality culture at Novartis.

Emily Harris, PharmD

Emily received a B.S. in biology from Quinnipiac University and a PharmD from MCPHS University. She is currently working towards a M.S. in Regulatory Affairs and Health Policy at MCPHS University. In July 2018, she started a two-year fellowship in Regulatory Affairs at Novartis Institutes for BioMedical Research as part of the MCPHS Pharmaceutical Industry Fellowship Program. As a fellow, Emily is responsible for providing strategic regulatory guidance for early phase clinical programs, as well as conducting regulatory intelligence research and supporting regulatory submissions.

 

Sonia Kumar, PharmD

Sonia Kumar graduated Rutgers University with a PharmD degree in 2018. She has done internships in drug supply management and medical writing. Currently she is the second year fellow at Novartis in Translational Clinical Oncology. In her role, she uses her pharmacy background to help inform colleagues on medication use in hospital pharmacies. Her interests include solid tumor oncology, early phase clinical trials, and precision medicine.

   

 

 

---

Release Date:  November 25, 2019
Expiration Date: November 25, 2020
Contact Hours:  1.0
ACPE UAN:  0026-0000-19-019-H03-P
ACPE Topic Designator:  Law

MA licensed pharmacists, please refer to MA BOP policy 2020-10 section VII for further information on the use CE credits designated for pharmacy law (03) and compounding (07) to meet annual licensure requirements. Pharmacists licensed outside of MA should refer to their own state boards of Pharmacy for more information.

Registration Fee: Free to all participants!